1. Frequent distribution of ultrarapid metabolisers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles;Aklillu;J. Pharmacol. Exp. Ther.,1996
2. R. The cytochrome P450 (CYP2D6) allelic variant CYP2D6J and related polymorphisms in a European population;Armstrong;Pharmacogenetics,1994
3. Asante–Poku, S.; Ofori–Adjei, D.; Johnson, T. K.; Gaedigk, A. Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. 1st pan-African Conf. Biochem. Mol. Biol. Nairobi, Kenya; September 2–6, 1996.
4. Importance of genetic factors in the regulation of diazepam phenotype;Bertilsson;Clin. Pharmacol. Ther.,1989
5. Bertilsson, L.; Lou, Y. Q.; Du, Y. L.; Liu, Y.; Kuang, T. Y.; Liao, X. M.; Wang, K. Y.; Iselius, L.; Sjöqvist, F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Ther. 51:388–397; 1992.